ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, 300mg/Pre-filled dual chamber syringe

( ARTG ) - ABILIFY is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - Acute treatment of manic or mixed episodes associated with Bipolar I Disorder in adults as monotherapy and in combination with lithium or valproate; - Maintenance treatment of manic or mixed episodes in Bipolar I Disorder in adults as monotherapy.